
Opinion|Videos|September 17, 2024
Navigating the Safety Profile of Ruxolitinib in cGVHD
Panelists discuss how to effectively manage the safety profile of ruxolitinib when used in the treatment of chronic graft-versus-host disease, addressing potential adverse effects and monitoring strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5







































